Explore

Reuters Reuters
AstraZeneca investors baulk at $400 billion Bristol Myers talks

AstraZeneca investors baulk at $400 billion Bristol Myers talks

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca's shares fell sharply on Monday as investors baulked at reports of merger talks with Bristol Myers Squibb about forming what would become one of the world's biggest drugmakers with a combined value of nearly $400 billion.
Trendline Trendline
Johnson Johnson, Coca-Cola, and Walmart Highlighted as Reliable Dividend Stocks for Long-Term Investment

Johnson Johnson, Coca-Cola, and Walmart Highlighted as Reliable Dividend Stocks for Long-Term Investment

Johnson Johnson, Coca-Cola, and Walmart Highlighted as Reliable Dividend Stocks for Long-Term Investment
Reuters Reuters
AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca investors punished the pharmaceutical firm on Monday over reports of merger talks with U.S. rival Bristol Myers Squibb that could make one of the world's biggest drugmakers with a combined value of nearly $400 billion.
TheStreet TheStreet
Morgan Stanley uncovers major Bristol Myers stock signals

Morgan Stanley uncovers major Bristol Myers stock signals

Bristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report and kept its rating exactly where it was. (The source of much of this article is a Morgan Stanley report shared with me.) Morgan Stanley sees the stock falling to $40, well ...
Trendline Trendline
Pfizer's Q2 2026 Earnings Highlight COVID's Impact on Revenue Guidance

Pfizer's Q2 2026 Earnings Highlight COVID's Impact on Revenue Guidance

Pfizer's Q2 2026 Earnings Highlight COVID's Impact on Revenue Guidance
Trendline Trendline
Moderna Reports Q2 2026 Earnings: Revenue Growth and Pipeline Expansion Amid Challenges

Moderna Reports Q2 2026 Earnings: Revenue Growth and Pipeline Expansion Amid Challenges

Moderna Reports Q2 2026 Earnings: Revenue Growth and Pipeline Expansion Amid Challenges
Trendline Trendline
Novartis Launches Postdoctoral Fellowship to Advance Predictive Medicine in Cardiovascular Research

Novartis Launches Postdoctoral Fellowship to Advance Predictive Medicine in Cardiovascular Research

Novartis Launches Postdoctoral Fellowship to Advance Predictive Medicine in Cardiovascular Research
Trendline Trendline
Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint
Trendline Trendline
Novo Nordisk Shares Drop After Heart Drug Trial Fails to Show Benefits

Novo Nordisk Shares Drop After Heart Drug Trial Fails to Show Benefits

Novo Nordisk Shares Drop After Heart Drug Trial Fails to Show Benefits
Trendline Trendline
Moderna Reports Q2 2026 Revenue of $145M Amid $782M Net Loss, Projects Revenue Growth

Moderna Reports Q2 2026 Revenue of $145M Amid $782M Net Loss, Projects Revenue Growth

Moderna Reports Q2 2026 Revenue of $145M Amid $782M Net Loss, Projects Revenue Growth
Trendline Trendline
Novartis Launches AI-Focused Postdoctoral Fellowship to Advance Cardiovascular Research

Novartis Launches AI-Focused Postdoctoral Fellowship to Advance Cardiovascular Research

Novartis Launches AI-Focused Postdoctoral Fellowship to Advance Cardiovascular Research
Trendline Trendline
Biotech Stocks BIOA and GLUE Plummet Following Novo Nordisk Trial Setback

Biotech Stocks BIOA and GLUE Plummet Following Novo Nordisk Trial Setback

Biotech Stocks BIOA and GLUE Plummet Following Novo Nordisk Trial Setback